Table 11Low potency statin in combination with ezetimibe as compared to high potency statin monotherapy in general populations: strength of evidence

OutcomeNo. Studies
(N)
Risk of BiasDirectnessConsistencyPrecisionReporting Bias

Other Issues
Findings and Magnitude of EffectStrength of Evidence
Long-Term Benefits and Serious Adverse Events
Mortality2aLowNAConsistentImpreciseNot detected

None
No deaths in any armInsufficient
Acute Coronary EventsNoneNANANANANANo eligible studiesInsufficient
Revascularization ProceduresNoneNANANANANANo eligible studiesInsufficient
Serious Adverse EventsNoneNANANANANANo eligible studiesInsufficient
Surrogate Clinical Outcomes
LDL-c13a
(2392)
ModerateIndirect

[LDL not directly measured in all trials]
Inconsistent

[six favored combination, three neutral, three monotherapy]
ImpreciseNot detected

None
Six comparisons favored combination therapy for lowering LDL-c as compared to monotherapy (difference 2 percent to 12 percent), three favored monotherapy, four showed no difference.Low
HDL-c11
(2128)
ModerateDirect

[HDL directly measured]
Inconsistent

[three favored combination, six neutral, one monotherapy]]
ImpreciseNot detected

None
Three comparisons favored combination therapy for raising HDL-c as compared to monotherapy (difference5.14 percent to 6.3 percent).Low

HDL = high-density lipoprotein; LDL = low-density lipoprotein; NA = not applicable

a

Missing N in at least one trial.

From: Results

Cover of Combination Therapy Versus Intensification of Statin Monotherapy: An Update
Combination Therapy Versus Intensification of Statin Monotherapy: An Update [Internet].
Comparative Effectiveness Reviews, No. 132.
Monroe AK, Gudzune KA, Sharma R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.